標(biāo)題: Titlebook: Handbook of Anticancer Pharmacokinetics and Pharmacodynamics; William D. Figg,Howard L. McLeod Book 20041st edition Humana Press 2004 DNA. [打印本頁(yè)] 作者: 會(huì)議記錄 時(shí)間: 2025-3-21 19:28
書(shū)目名稱(chēng)Handbook of Anticancer Pharmacokinetics and Pharmacodynamics影響因子(影響力)
書(shū)目名稱(chēng)Handbook of Anticancer Pharmacokinetics and Pharmacodynamics影響因子(影響力)學(xué)科排名
書(shū)目名稱(chēng)Handbook of Anticancer Pharmacokinetics and Pharmacodynamics網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱(chēng)Handbook of Anticancer Pharmacokinetics and Pharmacodynamics網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱(chēng)Handbook of Anticancer Pharmacokinetics and Pharmacodynamics被引頻次
書(shū)目名稱(chēng)Handbook of Anticancer Pharmacokinetics and Pharmacodynamics被引頻次學(xué)科排名
書(shū)目名稱(chēng)Handbook of Anticancer Pharmacokinetics and Pharmacodynamics年度引用
書(shū)目名稱(chēng)Handbook of Anticancer Pharmacokinetics and Pharmacodynamics年度引用學(xué)科排名
書(shū)目名稱(chēng)Handbook of Anticancer Pharmacokinetics and Pharmacodynamics讀者反饋
書(shū)目名稱(chēng)Handbook of Anticancer Pharmacokinetics and Pharmacodynamics讀者反饋學(xué)科排名
作者: Assault 時(shí)間: 2025-3-21 21:13 作者: 裝勇敢地做 時(shí)間: 2025-3-22 04:00
Mouse Models in Cancer Drug Discovery and Development,l proliferation either in tissue culture (in vitro) or in animals (in vivo), without specific reference to a molecular or cellular target of action. Indeed, the potentially useful effects of the vast majority of agents currently approved for use as safe and effective as oncologic therapeutics in hum作者: Trabeculoplasty 時(shí)間: 2025-3-22 05:57 作者: 使成波狀 時(shí)間: 2025-3-22 10:36 作者: gout109 時(shí)間: 2025-3-22 15:49 作者: arrogant 時(shí)間: 2025-3-22 19:03
Pharmacokinetic Modeling,s usually limited to the blood or plasma. Pharmacokinetic data analysis consists of examining plasma concentration—time data and estimating pharmacokinetic parameters that describe drug disposition. Methods used for pharmacokinetic analysis include noncompartmental analysis or pharmacokinetic modeli作者: 建筑師 時(shí)間: 2025-3-23 00:50 作者: Arroyo 時(shí)間: 2025-3-23 01:35 作者: 你敢命令 時(shí)間: 2025-3-23 05:37
Protein Binding of Anticancer Drugs,incingly for several important drugs .. Such tests generally are not appropriate for drugs of limited effectiveness and potency and in patients who respond well to the usual dosage regimen of a drug. They are also superfluous for drugs whose intensity of action can be judged accurately during their 作者: Restenosis 時(shí)間: 2025-3-23 11:50 作者: 精密 時(shí)間: 2025-3-23 17:17
Cytochrome P450 and Anticancer Drugs,on, reduction, and hydrolysis, effected by introducing a polar group into the parent molecule. The phase I reactions are followed by conjugations with hydrophilic compounds such as glucuronic acid and glutathione, to yield a more hydrophilic metabolite (phase II reactions). Cytochrome P450 (P450 or 作者: 護(hù)航艦 時(shí)間: 2025-3-23 18:14 作者: nugatory 時(shí)間: 2025-3-24 00:57
Drug Interactions,nt reviews .. Most patients receive multidrug combinations for their malignancy. Also, many of these patients are treated with intercurrent medication for co-morbidity or for cancer-related disorders (coagulopathy, infection, pain, seizures, etc.). The clinical significance of these potential drug i作者: Prognosis 時(shí)間: 2025-3-24 03:17
ABC Transporters, studied, although host factors and host-tumor interactions may also play critical roles. Cellular resistance mediated by a reduced accumulation of chemotherapy can be due to the expression of drug transporters in tumor cells. The ATP-binding cassette (ABC) transporters, the largest transporter fami作者: POWER 時(shí)間: 2025-3-24 08:09
Intrathecal Chemotherapy,itis or intraparenchymal metastases, is in part due to the pharmacologic sanctuary created by the blood-brain (BBB) and blood-cerebrospinal fluid (CSF) barriers. As a result, tumor cells within the CNS are protected from the cytotoxic effects of systemically administered chemotherapy. Leukemias and 作者: 注視 時(shí)間: 2025-3-24 14:32
Use of Microdialysis in Preclinical and Clinical Development of Anticancer Agents,nd to initial treatment or relapse after an initial response .. Thus, there is a need to identify factors associated with lack of response and to develop new treatment strategies that address those factors. The development of effective chemotherapeutic agents for the treatment of solid tumors depend作者: 明智的人 時(shí)間: 2025-3-24 15:16
Transbarrier Ion and Fluid Transport,eaths in 2020, even if the current trends remain unchanged .. Since the use of mustine to treat a patient with acute lymphoblastic leukemia in 1943 ., 92 anticancer drugs have been approved by the U.S. Food and Drug Administration (FDA). A recent World Health Organization (WHO) consultation consider作者: 四指套 時(shí)間: 2025-3-24 19:10
The Vertebrate IntegumentVolume 1entury. Although 92 approved anticancer drugs are available today for the treatment of more than 200 different tumor entities, effective therapies for most of these tumors are lacking .. Out of the 92 registered drugs, 17 are considered by oncologists to be more broadly applicable and 12 additional 作者: Spinal-Tap 時(shí)間: 2025-3-25 02:04
The Vertebrate Integument Volume 2l proliferation either in tissue culture (in vitro) or in animals (in vivo), without specific reference to a molecular or cellular target of action. Indeed, the potentially useful effects of the vast majority of agents currently approved for use as safe and effective as oncologic therapeutics in hum作者: 意外的成功 時(shí)間: 2025-3-25 03:43
https://doi.org/10.1007/978-1-137-51246-8ular-weight (hydroxyurea) as well as high-molecular-weight organic compounds (bleomycin) are represented. Thus, almost every drug will require evaluation of optimal conditions for sample handling and analytical procedures. The situation is complicated further by the fact that the given drug can be i作者: 怎樣才咆哮 時(shí)間: 2025-3-25 10:43
https://doi.org/10.1007/978-1-4612-5902-2oach most often used for anticancer drugs. The discipline has progressed from one that was in its infancy a decade ago to a largely mature endeavor more recently. Validation and control procedures in other areas of bioanalysis such as clinical chemistry and forensic toxicology have been largely cons作者: 西瓜 時(shí)間: 2025-3-25 13:45
https://doi.org/10.1007/978-3-0348-0215-4linical pharmacology facilitates the clinician prescribing optimal therapy to an individual patient. Over the last 30 yr the clinical pharmacology of many drugs has been elucidated with advances in sophisticated, accurate, and precise analytical tools to determine plasma drug and/or metabolite conce作者: palliate 時(shí)間: 2025-3-25 16:08 作者: Perceive 時(shí)間: 2025-3-25 22:58
The Viability of Organizations Vol. 2 typically plasma or serum; however, analytes may be measured at other sites such as cerebrospinal fluid, ascitic fluid, or another easily accessible tissue or fluid. While pharmacokinetic modeling enables prediction of plasma drug concentrations following dose administration, application of a pharm作者: CLOWN 時(shí)間: 2025-3-26 02:27
Design Guidelines and Scenarios—A Summarying data, and when it is interpreted in light of development goals and other knowledge, then an understanding is gained of the direction that future development ought to take. In the current drug development climate volumes of data are generated but little emphasis is placed on knowledge generation 作者: 控訴 時(shí)間: 2025-3-26 07:50 作者: GILD 時(shí)間: 2025-3-26 09:35
,“Looking Yonderly”: Mary Taylor’s , (1890),or to sites of potential toxicity (Fig. 1). The chemical modification of xenobiotics may be viewed as a means to increase the hydrophilic nature of the substrate molecule or to introduce chemical substituent moieties, which are then better substrates for subsequent conjugation. Although the division作者: Barter 時(shí)間: 2025-3-26 15:10 作者: Entirety 時(shí)間: 2025-3-26 18:27 作者: arthroscopy 時(shí)間: 2025-3-26 21:08 作者: 個(gè)人長(zhǎng)篇演說(shuō) 時(shí)間: 2025-3-27 02:47 作者: Hallmark 時(shí)間: 2025-3-27 07:17 作者: FLORA 時(shí)間: 2025-3-27 11:38 作者: commonsense 時(shí)間: 2025-3-27 15:23
Transbarrier Ion and Fluid Transport,of new anticancer drugs has improved survival in a few diseases such as childhood leukemia and testicular cancer, there is an urgent need to continue to develop new and improved agents, as well as to optimize the use of conventional drugs.作者: PANT 時(shí)間: 2025-3-27 19:10
,“Looking Yonderly”: Mary Taylor’s , (1890),n of phase I reactions are oxidative, and the majority of oxidative metabolic reactions are mediated by the cytochrome P450 (CYP) superfamily of enzymes. The CYP enzymes are the subject of the next chapter.作者: OFF 時(shí)間: 2025-3-27 21:56 作者: Entirety 時(shí)間: 2025-3-28 06:01 作者: cajole 時(shí)間: 2025-3-28 08:59 作者: TOXIN 時(shí)間: 2025-3-28 12:08 作者: placebo 時(shí)間: 2025-3-28 18:03 作者: Nuance 時(shí)間: 2025-3-28 20:05
Intrathecal Chemotherapy, within the CNS including breast and small-cell lung cancer .; primary CNS tumors such as medulloblastoma and glioma .,.; and childhood tumors such as neuroblastoma, retinoblastoma, and rhabdomyosarcoma ..作者: 消散 時(shí)間: 2025-3-28 23:47 作者: 肥料 時(shí)間: 2025-3-29 06:05 作者: 母豬 時(shí)間: 2025-3-29 11:04 作者: Hallowed 時(shí)間: 2025-3-29 14:42
The Viability of Organizations Vol. 1ng. Noncompartmental analysis does not depend on fitting mathematical models to the drug disposition data. Compartmental analysis is the most often used pharmacokinetic modeling approach. This chapter discusses various aspects of compartmental modeling.作者: 合同 時(shí)間: 2025-3-29 18:10 作者: flimsy 時(shí)間: 2025-3-29 20:10
Pharmacokinetic Modeling,ng. Noncompartmental analysis does not depend on fitting mathematical models to the drug disposition data. Compartmental analysis is the most often used pharmacokinetic modeling approach. This chapter discusses various aspects of compartmental modeling.作者: maintenance 時(shí)間: 2025-3-30 02:59 作者: 1FAWN 時(shí)間: 2025-3-30 04:07
2196-9906 ent and validation of bioanalytic methods. The chapters on identifying agents to test in phase III trials and on trial design for the approval of new anticancer agents offer a unique roadmap for moving an agent to NDA submission.978-1-59259-734-5Series ISSN 2196-9906 Series E-ISSN 2196-9914 作者: 燈絲 時(shí)間: 2025-3-30 08:49 作者: Arbitrary 時(shí)間: 2025-3-30 14:53
https://doi.org/10.1007/978-1-349-17060-9lop new treatment strategies that address those factors. The development of effective chemotherapeutic agents for the treatment of solid tumors depends, in part, on the ability of those agents to achieve cytotoxic drug concentrations or exposure within the tumor ..作者: Occipital-Lobe 時(shí)間: 2025-3-30 18:28
Design Guidelines and Scenarios—A Summaryhe process of knowledge discovery when applied to PM model development ensures that information embedded in the data is thoroughly understood and apporopriately applied .. Modern data analysis methods and modern statistical software such as S-Plus. have revolutionized the manner in which PM analyses can be performed.作者: BLOT 時(shí)間: 2025-3-30 21:58 作者: vanquish 時(shí)間: 2025-3-31 00:58
Preclinical Screening for New Anticancer Agents,r activity. Only a certain number of drugs and concepts, however, can be evaluated clinically because of cost and ethical considerations. A preselection, called the screening process, is therefore required. The aim of screening efforts is to identify products that will produce antitumor effects matc作者: 忍耐 時(shí)間: 2025-3-31 06:10 作者: Motilin 時(shí)間: 2025-3-31 10:06
